The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...
51mon MSN
Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to crown any winners in the race for the next generation of anti-obesity ...
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...
Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...
New diet drugs are making it easier to lose weight. So does that mean we can stop exercising? Health experts say no. There is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback